Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Korro Bio, Inc. (KRRO : NSDQ)
 
 • Company Description   
Korro Bio Inc. is an RNA editing company focused on the discovery and development of a new class of precision genetic medicines for both rare and highly prevalent diseases. Korro Bio Inc., formerly known as Frequency Therapeutics Inc., is based in LEXINGTON, Mass.

Number of Employees: 58

 
 • Price / Volume Information   
Yesterday's Closing Price: $12.24 Daily Weekly Monthly
20 Day Moving Average: 73,130 shares
Shares Outstanding: 14.73 (millions)
Market Capitalization: $180.24 (millions)
Beta: 3.09
52 Week High: $55.89
52 Week Low: $5.20
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -9.27% -8.86%
12 Week 4.97% 2.74%
Year To Date 52.81% 35.52%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
60 FIRST STREET 2ND FLOOR SUITE 250
-
CAMBRIDGE,MA 02141
USA
ph: 617-468-1999
fax: -
ir@korrobio.com http://www.korrobio.com
 
 • General Corporate Information   
Officers
Ram Aiyar - President; Chief Executive Officer and Director
Oliver Dolan - Senior Vice President; Finance
Ali Behbahani - Director
Nessan Bermingham - Director
Jean-Francois Formela - Director

Peer Information
Korro Bio, Inc. (GSAC)
Korro Bio, Inc. (CASIF)
Korro Bio, Inc. (ALCD.)
Korro Bio, Inc. (OMNN)
Korro Bio, Inc. (CGPI.)
Korro Bio, Inc. (CATX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-DRUGS
Sector: Medical
CUSIP: 500946108
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 06/01/26
Next Expected EPS Date: 11/11/26
Share - Related Items
Shares Outstanding: 14.73
Most Recent Split Date: 11.00 (0.02:1)
Beta: 3.09
Market Capitalization: $180.24 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-1.25 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-4.97 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 8.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 11/11/26  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.71
Price/Cash Flow: -
Price / Sales: 28.20
EPS Growth
vs. Year Ago Period: 60.95%
vs. Previous Quarter: 36.69%
Sales Growth
vs. Year Ago Period: -43.11%
vs. Previous Quarter: 18.53%
ROE
06/30/26 - -114.26
03/31/26 - -117.86
12/31/25 - -115.95
ROA
06/30/26 - -68.57
03/31/26 - -71.04
12/31/25 - -71.32
Current Ratio
06/30/26 - 9.55
03/31/26 - 8.13
12/31/25 - 6.90
Quick Ratio
06/30/26 - 9.55
03/31/26 - 8.13
12/31/25 - 6.90
Operating Margin
06/30/26 - -
03/31/26 - -
12/31/25 - -1,834.48
Net Margin
06/30/26 - -
03/31/26 - -
12/31/25 - -1,834.48
Pre-Tax Margin
06/30/26 - -4,441.85
03/31/26 - -2,935.09
12/31/25 - -1,824.52
Book Value
06/30/26 - 7.16
03/31/26 - 8.29
12/31/25 - 5.46
Inventory Turnover
06/30/26 - -
03/31/26 - -
12/31/25 - -
Debt-to-Equity
06/30/26 - 0.00
03/31/26 - 0.00
12/31/25 - 0.00
Debt-to-Capital
06/30/26 - 0.00
03/31/26 - 0.00
12/31/25 - 0.00
 

Powered by Zacks Investment Research ©